In a study by Bright et al. [89], the effects of NU7441, another DNA-PKcs inhibitor, in parallel with other inhibitors targeting the DNA damage response (e.g., ATM, ATR, RAD51, PARP), was investigated in combination with proton (9.9 keV/μm) or X-irradiation in lung cancer (H460 and H1299), pancreatic cancer (PANC-1 and Panc 10.05), and normal endothelial (HUVEC) cells. Here, ATM is linked to lung carcinoma.